GH Research Raises $117.5M in Dilutive Offering to Fund Phase 3, but Key Design Details Remain Undisclosed

What happened

GH Research priced a $117.5M underwritten offering of 6.5M shares at $18 each, diluting existing holders by ~10.5% but bolstering cash for Phase 3 preparations. The raise capitalizes on the post-clinical-hold stock price recovery, yet the company still lacks an FDA-aligned Phase 3 design disclosure, leaving the next gating item unresolved. While the strengthened balance sheet reduces near-term financing risk, the added shares lower our base case implied value from $16 to roughly $14.50 per share on a comparable enterprise basis. The market will now scrutinize management's ability to deliver protocol transparency and initiation timelines, as cash alone does not de-risk the pivotal program. We maintain our WAIT rating, as valuation hinges on execution milestones rather than liquidity.

Implication

The strengthened cash position provides runway through Phase 3 initiation and reduces the probability of a distressed financing, allowing the company to focus on operational milestones that drive long-term value.

Thesis delta

The offering reduces near-term financing risk but at the cost of dilution, lowering our base case per-share value. The core thesis remains unchanged: value creation depends on FDA-aligned Phase 3 design and start, not cash position. We adjust our scenarios downward by ~10% to reflect the increased share count, maintaining a WAIT rating until protocol-level disclosure.